Goto Teiichi

Goto Teiichi leads Fujifilm Holdings as President and CEO, continuing the corporate transformation that is widely considered one of the most remarkable strategic pivots in business history. While Eastman Kodak — Fujifilm's historic rival — filed for bankruptcy in 2012 as digital photography destroyed film demand, Fujifilm leveraged its core competencies in chemistry, materials science, optics, and imaging to diversify into entirely new industries. Fujifilm today operates in four segments: Healthcare (medical imaging systems, endoscopes — Fujifilm is a global leader alongside Olympus, pharmaceutical CDMO services through Fujifilm Diosynth Biotechnologies — a rapidly growing contract manufacturer of biologics), Imaging (instant cameras under the Instax brand — a surprise hit with younger generations, digital cameras, photo printing), Electronic Materials (CMP slurry, photoresists, display films — critical materials for semiconductor and display manufacturing), and Business Innovation (formerly Fuji Xerox — document management, printing, IT solutions). The healthcare and electronic materials segments drive the growth narrative: Fujifilm Diosynth Biotechnologies is expanding manufacturing capacity to meet growing demand for biologic drug production (antibodies, cell and gene therapies), while the electronic materials business benefits from semiconductor industry growth. Key stock drivers include healthcare segment growth (endoscopy, CDMO demand), electronic materials demand from semiconductor fabs, Instax camera/film sales, business solutions profitability, yen exchange rate, competitive dynamics in medical imaging (against Olympus, Siemens Healthineers), and the overall pace of biologic drug development.